Skip to main content
ChenDermatologist
ChenDermatologist
Dr. Chen Yi-Jia · Dermatology Notes
English version. Prefer Traditional Chinese? Switch to Chinese
Patient education · Psoriasis / Comorbidities Per AAD-NPF 2019/2020 + UpToDate 2024 · Updated 2026-05-09

Psoriasis comorbidities & special populations
PsA, CV, pregnancy, pediatric, nail, erythrodermic

Psoriasis is not just a skin disease — it is systemic inflammation. AAD-NPF 2019 comorbidities guideline mandates screening for seven essentials: psoriatic arthritis (15-30%), cardiovascular disease, metabolic syndrome, T2DM, NAFLD, depression/anxiety/suicidality, IBD. Special populations covered: pregnancy/lactation (certolizumab safest), pediatric (ustekinumab/secukinumab/ixekizumab approved ≥ 6 y), nail psoriasis, erythrodermic emergency (cyclosporine/infliximab first-line).

Note: Comorbidity screening and special-population management cross multiple specialties (rheumatology, cardiology, hepatology, endocrinology, psychiatry, OB/GYN, pediatrics). Individualized care required. Patient education only.
Key Fact (Elmets 2019, JAAD · Menter 2020, JAAD pediatric)

10-year CV event risk is elevated in moderate-severe psoriasis, equivalent to the level seen in diabetic patients (Mehta 2010, Am J Med）。Psoriatic arthritis (PsA), if undiagnosed in time, — within 5 years can cause irreversible joint destruction and impair function. AAD recommends that all psoriasis patients should "Ask about joint symptoms annually" + "routine cardiovascular / metabolic / mood screening".Pregnancy: 50% of psoriasis patients improve spontaneously during pregnancy; postpartum flare is common — drug selection requires special care.

Seven essential comorbidity screens

  • Psoriatic arthritis (PsA) — 15–30% prevalence; PEST screen yearly; refer to rheumatology if morning stiffness > 30 min, dactylitis, enthesitis, or DIP arthritis.
  • Cardiovascular disease — MI/stroke risk ↑ 1.4–3×; annual BP, BMI, waist, fasting glucose, lipid panel; treat ASCVD risk like a diabetic.
  • Metabolic syndrome / obesity / T2DM — OR 1.5–2×; 5–10% weight loss improves PASI by ≥ 50%.
  • NAFLD / MASLD — prevalence ~47% in psoriasis; rule out before MTX; biologics safer.
  • Depression / anxiety / suicidality — yearly PHQ-2; brodalumab carries suicidality warning.
  • IBD — Crohn OR 2.5, UC 1.7; IL-17 inhibitors may worsen IBD; prefer TNFi or IL-23i (guselkumab/risankizumab also treat IBD).
  • Uveitis, lymphoma (slight ↑ SIR), CKD.

Pregnancy

50% improve, 25% unchanged, 25% worsen; 60% postpartum flare. Safe: low-mid potency topical steroids (limited area), NB-UVB (with folate), certolizumab pegol (no transplacental due to no Fc). Avoid: methotrexate (3-month wash-out), acitretin (3-year wash-out), PUVA, tazarotene. Acute generalized pustular psoriasis of pregnancy (impetigo herpetiformis): cyclosporine + systemic steroid + admission; spesolimab (anti-IL-36R) approved for GPP.

Pediatric psoriasis

Prevalence ~1%; 1/3 onset before 18; guttate (post-strep) and plaque most common. Topicals first-line. Approved pediatric biologics: etanercept ≥ 4 y, ustekinumab ≥ 6 y, ixekizumab ≥ 6 y, secukinumab ≥ 6 y (BAD 2023 expansion), adalimumab ≥ 4 y (region-dependent). Avoid PUVA in young children. Screen comorbidities (BMI, BP, PsA, mood) like adults.

Nail psoriasis

50% of skin psoriasis; matrix signs (pitting, leukonychia, red lunula, crumbling) and bed signs (oil-drop, onycholysis, subungual hyperkeratosis, splinter hemorrhage). Mild: topical calcipotriol/tazarotene to nail folds. Moderate: intralesional triamcinolone every 4–8 weeks. Severe (multi-digit, high QoL impact): systemic — IL-17i (ixekizumab), IL-23i (risankizumab), TNFi (adalimumab, infliximab) reach 50–70% NAPSI clearance.

Erythrodermic psoriasis — emergency

> 90% BSA erythema with scale; mortality 4–64%. Triggers: abrupt steroid withdrawal, infection, lithium, antimalarials. Admit; monitor temp, fluids, electrolytes, albumin; bland topicals + low-potency steroid + wet wraps. First-line systemic: cyclosporine (2–5 mg/kg/day) or infliximab (rapid onset). Transition to maintenance IL-17i/IL-23i/ustekinumab. Avoid slow-onset agents (MTX, acitretin) in the acute phase.

Bottom line

Psoriasis is systemic. Annual comorbidity screening (joints, BP, glucose, lipids, mood, DLQI) reduces long-term cardiovascular, disability, and suicide risk. Pregnancy, pediatric, nail, and erythrodermic disease all have evidence-based protocols — don't dismiss psoriasis as "just skin".